Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Rivaroxaban 10 mg vs Xarelto 10 mg in healthy Thai volunteers under fasting conditions
TCTR20201123001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), deep vein thrombosis (DVT) and 1 more (2 arms), sponsored by Bio-innova. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on TCTR20201123001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201123001.